Abstracts

W96 EFFICACY OF 4/7 DAYS MAINTENANCE ART STRATEGY: ANRS-170 QUATUOR TRIAL

Intermittent treatment could improve the convenience, tolerability and cost of ART. We have previously demonstrated in the QUATUOR trial the non-inferiority of maintenance 4 days-a-week (4/7days) versus 7/7days in patients (pts) under triple therapy with either PI, NNRTI, or InSTI based regimen: 95.6% vs 97.2% treatment success at W48. ClinicalTrials.gov:NCT03256422. We report here the W96…

STRUCTURAL BASIS FOR VIRAL RESISTANCE TO LONG-ACTING HIV-1 CAPSID INHIBITOR GS-6207

GS-6207 (Lenacapavir, Gilead Sciences) is an experimental long-acting and highly potent HIV-1 capsid (CA) inhibitor. Viral breakthrough assays in cell culture identified a number of HIV-1 CA substitutions including M66I, Q67H, N74D and Q67H/N74D that confer substantial resistance to the inhibitor. Furthermore, the Q67H capsid substitution has emerged in HIV-1 infected patients receiving GS-6207. We…